Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

Zoetis Inc. (ZTS) EV/Sales Ratio: 4.39x

Is Zoetis Inc.’s EV/Sales ratio high or low?

Zoetis Inc.'s EV/Sales ratio of 4.39x is 56% below its 5-year average of 9.90x, near the low end of its 5-year range (4.06x–15.91x).

The EV/Sales ratio for Zoetis Inc. (ZTS) is 4.39x as of Wednesday, June 10, 2026. It is below its 12-month average by 34.73% (6.73x).

ZTS EV/Sales Ratio Chart

ZTS EV/Sales Ratio
4.39x-48.95% 1Y
Zoom

ZTS Average EV/Sales Ratio Chart

ZTS Current vs Average EV/Sales Ratio Chart

ZTS EV/Sales Ratio Metrics

EV/SALES RATIO

4.39x

EV/SALES RATIO AVG TTM

6.73x

EV/SALES RATIO AVG 3Y

8.78x

EV/SALES RATIO AVG 5Y

9.90x

EV/SALES RATIO AVG 10Y

9.48x

EV/SALES RATIO AVG 15Y

8.30x

EV/SALES RATIO AVG 20Y

8.30x

CURRENT VS TTM AVG

-34.73%

CURRENT VS 3Y AVG

-49.99%

CURRENT VS 5Y AVG

-55.67%

CURRENT VS 10Y AVG

-53.71%

CURRENT VS 15Y AVG

-47.12%

CURRENT VS 20Y AVG

-47.12%

ZTS Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Zoetis Inc. (ZTS)4.39x6.73x8.78x9.90x
Centene Corporation (CNC)$31.94B0.14x0.11x0.20x0.29x
IQVIA Holdings Inc. (IQV)$30.60B1.88x2.83x3.22x3.53x
Agilent Technologies, Inc. (A)$38.26B5.53x5.56x5.75x6.21x
DexCom, Inc. (DXCM)$29.24B6.23x6.64x10.22x13.89x
Biogen Inc. (BIIB)$29.00B3.28x2.79x3.30x3.58x
Veeva Systems Inc. (VEEV)$27.37B7.85x12.54x13.33x15.72x
Humana Inc. (HUM)$43.78B0.39x0.30x0.40x0.54x
IDEXX Laboratories, Inc. (IDXX)$44.47B10.42x12.34x11.51x12.39x
Waters Corporation (WAT)$23.83B9.32x7.03x7.13x7.32x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Zoetis Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Zoetis Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for Zoetis Inc. (ZTS)?
The EV/Sales ratio for ZTS stock is 4.39x.
Is Zoetis Inc.'s EV/Sales ratio high or low?
Zoetis Inc.'s EV/Sales ratio of 4.39x is 56% below its 5-year average of 9.90x, near the low end of its 5-year range (4.06x–15.91x).
What is the TTM average EV/Sales ratio for Zoetis Inc. (ZTS)?
The TTM average EV/Sales ratio for ZTS stock is 6.73x.
What is the 3Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
The 3Y average EV/Sales ratio for ZTS stock is 8.78x.
What is the 5Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
The 5Y average EV/Sales ratio for ZTS stock is 9.90x.
What is the 10Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
The 10Y average EV/Sales ratio for ZTS stock is 9.48x.
What is the 15Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
The 15Y average EV/Sales ratio for ZTS stock is 8.30x.
What is the 20Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
The 20Y average EV/Sales ratio for ZTS stock is 8.30x.

Zoetis Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-104.39x
2026-06-094.42x
2026-06-084.27x
2026-06-054.30x
2026-06-044.30x
2026-06-034.21x
2026-06-024.16x
2026-06-014.21x
2026-05-294.22x
2026-05-284.24x
2026-05-274.30x
2026-05-264.33x
2026-05-224.38x
2026-05-214.32x
2026-05-204.31x
2026-05-194.27x
2026-05-184.22x
2026-05-154.06x
2026-05-144.12x
2026-05-134.07x
2026-05-124.19x
2026-05-114.17x
2026-05-084.45x
2026-05-074.65x
2026-05-065.91x
2026-05-055.97x
2026-05-045.98x
2026-05-016.05x
2026-04-306.09x
2026-04-296.03x
2026-04-286.16x
2026-04-276.22x
2026-04-246.17x
2026-04-236.14x
2026-04-226.20x
2026-04-216.23x
2026-04-206.44x
2026-04-176.43x
2026-04-166.27x
2026-04-156.35x
2026-04-146.37x
2026-04-136.32x
2026-04-106.22x
2026-04-096.32x
2026-04-086.31x
2026-04-076.17x
2026-04-066.24x
2026-04-026.22x
2026-04-016.19x
2026-03-316.24x
2026-03-306.15x
2026-03-276.01x
2026-03-266.16x
2026-03-256.17x
2026-03-246.13x
2026-03-236.10x
2026-03-206.12x
2026-03-196.13x
2026-03-186.20x
2026-03-176.40x
2026-03-166.23x
2026-03-136.12x
2026-03-126.11x
2026-03-116.31x
2026-03-106.34x
2026-03-096.43x
2026-03-066.38x
2026-03-056.42x
2026-03-046.59x
2026-03-036.59x
2026-03-026.73x
2026-02-276.83x
2026-02-266.77x
2026-02-256.73x
2026-02-246.72x
2026-02-236.59x
2026-02-206.73x
2026-02-196.66x
2026-02-186.74x
2026-02-176.58x
2026-02-136.63x
2026-02-126.58x
2026-02-116.62x
2026-02-106.60x
2026-02-096.56x
2026-02-066.56x
2026-02-056.53x
2026-02-046.53x
2026-02-036.33x
2026-02-026.44x
2026-01-306.44x
2026-01-296.29x
2026-01-286.30x
2026-01-276.45x
2026-01-266.40x
2026-01-236.40x
2026-01-226.42x
2026-01-216.45x
2026-01-206.36x
2026-01-166.43x
2026-01-156.46x
2026-01-146.49x
2026-01-136.43x
2026-01-126.46x
2026-01-096.55x
2026-01-086.53x
2026-01-076.48x
2026-01-066.65x
2026-01-056.65x
2026-01-026.49x
2025-12-316.49x
2025-12-306.51x
2025-12-296.49x
2025-12-266.51x
2025-12-246.47x
2025-12-236.38x
2025-12-226.39x
2025-12-196.32x
2025-12-186.34x
2025-12-176.32x
2025-12-166.36x
2025-12-156.26x
2025-12-126.15x
2025-12-116.10x
2025-12-106.12x
2025-12-096.01x
2025-12-086.13x
2025-12-056.15x
2025-12-046.23x
2025-12-036.33x
2025-12-026.42x
2025-12-016.55x
2025-11-286.60x
2025-11-266.57x
2025-11-256.58x
2025-11-246.35x
2025-11-216.31x
2025-11-206.02x
2025-11-196.07x
2025-11-186.12x
2025-11-176.16x
2025-11-146.25x
2025-11-136.27x
2025-11-126.27x
2025-11-116.22x
2025-11-106.20x
2025-11-076.22x
2025-11-066.19x
2025-11-056.23x
2025-11-046.42x
2025-11-037.42x
2025-10-317.41x
2025-10-307.41x
2025-10-297.40x
2025-10-287.47x
2025-10-277.57x
2025-10-247.50x
2025-10-237.52x
2025-10-227.55x
2025-10-217.51x
2025-10-207.46x
2025-10-177.41x
2025-10-167.37x
2025-10-157.32x
2025-10-147.38x
2025-10-137.32x
2025-10-107.27x
2025-10-097.38x
2025-10-087.38x
2025-10-077.35x
2025-10-067.47x
2025-10-037.52x
2025-10-027.52x
2025-10-017.55x
2025-09-307.52x
2025-09-297.36x
2025-09-267.38x
2025-09-257.27x
2025-09-247.30x
2025-09-237.34x
2025-09-227.44x
2025-09-197.50x
2025-09-187.55x
2025-09-177.55x
2025-09-167.57x
2025-09-157.51x
2025-09-127.61x
2025-09-117.72x
2025-09-107.66x
2025-09-097.68x
2025-09-087.77x
2025-09-057.85x
2025-09-047.84x
2025-09-037.81x
2025-09-027.83x
2025-08-297.99x
2025-08-287.92x
2025-08-277.95x
2025-08-267.92x
2025-08-257.94x
2025-08-228.01x
2025-08-217.96x
2025-08-208.01x
2025-08-197.96x
2025-08-187.80x
2025-08-157.89x
2025-08-147.84x
2025-08-137.81x
2025-08-127.68x
2025-08-117.64x
2025-08-087.57x
2025-08-077.61x
2025-08-067.52x
2025-08-057.51x
2025-08-047.87x
2025-08-017.65x
2025-07-317.58x
2025-07-307.72x
2025-07-297.83x
2025-07-287.81x
2025-07-257.88x
2025-07-247.91x
2025-07-237.94x
2025-07-227.84x
2025-07-217.65x
2025-07-187.71x
2025-07-177.78x
2025-07-167.85x
2025-07-157.92x
2025-07-148.05x
2025-07-118.02x
2025-07-108.20x
2025-07-098.18x
2025-07-088.15x
2025-07-078.12x
2025-07-038.22x
2025-07-028.22x
2025-07-018.22x
2025-06-308.07x
2025-06-278.08x
2025-06-268.06x
2025-06-258.13x
2025-06-248.15x
2025-06-238.13x
2025-06-208.12x
2025-06-188.02x
2025-06-178.34x
2025-06-168.47x
2025-06-138.47x
2025-06-128.69x
2025-06-118.57x
2025-06-108.60x
2025-06-098.48x
2025-06-068.75x
2025-06-058.68x
2025-06-048.68x
2025-06-038.76x
2025-06-028.72x
2025-05-308.68x
2025-05-298.61x

Showing the most recent 260 of 3,359 data points. The chart above shows the full history.

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck